Pegozafermin, a fibroblast growth factor 21 (FGF21) analogue, improved fibrosis without worsening the disease in MASH patients treated with three doses (15, 30, and 44 mg) for 24 months. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.